Pure red cell aplasia due to follow-on epoetin

Kidney International

Volumn 74, Issue 12, 2008, Pages 1617-1622

  Keithi Reddy, Sai Ram ^a   Kandasamy, Sadayandi ^b   Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KOVAI MEDICAL CENTER AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; FERRIC HYDROXIDE SUCROSE; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS; UNCLASSIFIED DRUG; WEPOX;

ADULT; ANEMIA; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA;

EPOETIN ALFA; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL; RED-CELL APLASIA, PURE; RENAL DIALYSIS;

EID: 57049111999     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.230     Document Type: Article

References (26)

1. Kaznelson P. Zur Enstehung der Blut Plattchen. Verh Dtsch Ges Inn Med 1922; 34: 557.
2. Young NS. Pure red cell aplasia. In: Lichtman MAB, Ernest Kipps, Thomas J Seligsohn, Uri Kaushansky, Kenneth Prchal, Josef T (eds). Williams Hematology, 7th edn, vol. 34 McGraw-Hill Health Professions Division: New York, NY, 2006; 437-447.
3. Halperin DS, Freedman MH. Diamond-blackfan anemia: etiology, pathophysiology, and treatment. Am J Pediatr Hematol/Oncol 1989; 11: 380-394.
4. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87: 3000-3006.
5. Montagnac R, Boffa GA, Schillinger F et al. Sensitization to recombinant human erythropoietin in a woman under hemodialysis. Presse Med 1992; 21: 84-85.
6. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475.
7. Ryan MH, Heavner GA, Brigham-Burke M et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol 2006; 6: 647-655.
8. Sharma B, Bader F, Templeman T et al. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX. Eur J Hosp Pharm 2004; 5: 86-91.
9. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408.
10. K/DOQI. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-S145.
11. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii32-ii36.
12. Covic A, Kuhlmann MK. Biosimilars: recent developments. Int Urol Nephrol 2007; 39: 261-266.
13. Dove A. Uncorking the biomanufacturing bottleneck. Nat Biotechnol 2002; 20: 777-779.
14. Restelli V, Wang MD, Huzel N et al. The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells. Biotechnol Bioeng 2006; 94: 481-494.
15. Misaizu T, Matsuki S, Strickland TW et al. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 1995; 86: 4097-4104.
16. Schellekens H. How similar do 'biosimilars' need to be? Nat Biotechnol 2004; 22: 1357-1359.
17. Schellekens H. When biotech proteins go off-patent. Trends Biotechnol 2004; 22: 406-410.
18. Singh A. Gaps in the quality and potential safety of biosimilar epoetins in the developing world: an international survey. In American Society of Nephrology: Renal Week 2006.
19. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005; 25: 954-962.
20. Ramos AS, Schmidt CA, Andrade SS et al. Biological evaluation of recombinant human erythropoietin in pharmaceutical products. Braz J Med Biol Res 2003; 36: 1561-1569.
21. Hermeling S, Aranha L, Damen JM et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005; 22: 1997-2006.
22. Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005; 20(Suppl 4): iv23-iv26.
23. Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-3347.
24. Verhelst D, Rossert J, Casadevall N et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363: 1768-1771.
25. Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108: 1830-1834.
26. Woodburn KW, Fan Q, Winslow S et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35: 1201-1208.